- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05208281
En multi-kohorte undersøgelse af sikkerhed, effektivitet, PK og PD af GNR-055 hos patienter med mucopolysaccharidosis type II
Multicenter, open-label, multikohorteundersøgelse til evaluering af sikkerhed, farmakokinetik, farmakodynamik og effektivitet af lægemiddelprodukt GNR 055 (JSC "GENERIUM", Rusland) hos patienter med mucopolysaccharidosis type II
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
GNR-055 is intended for ERT in patient with Mucopolysaccharidosis type II (MPS II), or Hunter syndrome. MPS II is a recessive X-linked inheritance lysosomal storage disease, which is characterized by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (ID2S), caused by a mutation in the ID2S gene. Enzyme deficiency leads to the accumulation of Glycosaminoglycans (GAG) (mainly of heparan and dermatan sulfates) in lysosomes of almost all types of cells of various tissues and organs. The disease is manifested by growth retardation, damage of many organs and systems, severe deformations of bones and joints, gross facial features, pathology of the respiratory and cardiovascular systems, damage to parenchymal organs (hepatosplenomegaly), and hearing impairment. A severe form of the disease occurs with the involvement of the nervous system in the pathological process, including mental retardation, behavior anomalies, and impaired motor function.
GNR-055 is a recombinant modified ID2S capable to penetrate the blood-brain barrier and thus expected to prevent neurodegenerative consequences and the cognitive deficit and to attain a significant improvement in the life quality and expectancy of patients with MPS II.
Study IDB-MPS-II-III is a multicenter, open-label, multi-cohort study to assess safety, PK and PD, and efficacy of GNR-055 in patients of different age groups with MPS II (Hunter syndrome).
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Moscow, Rusland, 119333
- Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences)
-
Saint Petersburg, Rusland, 194100
- Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation
-
Simferopol, Rusland, 295007
- V.I. Vernadsky Crimean Federal University
-
Ufa, Rusland, 450076
- State Budgetary Healthcare Institution Republican Medical Genetic Center
-
Yekaterinburg, Rusland, 620149
- State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Signed inform consent;
- Verified diagnosis of MPS II (Hunter syndrome);
- Naïve patients or patients who have received standard ERT whit idursulfase products;
- No contraindications for lumbar puncture as judged by the Investigator;
- Willingness and ability to follow study procedures.
Exclusion Criteria:
- Clinically pronounced hypersensitivity to ID2S or any other component of the drug product;
- History of hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation;
- Implanted or external non-removable metal devices, a cardiac pacemaker, or other objects sensitive to the magnetic field that may pose a danger to both the wearer and the correct operation of magnetic resonance imaging (MRI) equipment;
- Concomitant diseases and conditions that, in the Investigator's opinion, can put at risk the patient's safety during his/her participation in the study, or which will influence the safety data analysis in case of the disease/condition exacerbation during the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Adult: GNR-055
GNR-055: 1.0-2.0-3.0 mg/kg |
Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
Andre navne:
|
|
Eksperimentel: Paediatric: GNR-055 2.0 mg/kg
GNR-055 2.0 mg/kg |
Weekly IV infusion (lyophilized powder) 2.0 mg/kg
Andre navne:
|
|
Eksperimentel: Paediatric: GNR-055 3.0 mg/kg
GNR-055 3.0 mg/kg |
Weekly IV infusion (lyophilized powder) 3.0 mg/kg
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline to Week 56
|
Safety assessment will be performed based on the subjective complaints, physical examination, assessment of vital signs, laboratory tests, and 12-lead ECG; Incidence of allergic and infusion-related reactions; Incidence of Anti-Drug Antibodies (ADAs) against GNR-055 and their neutralizing activity. |
Baseline to Week 56
|
|
Urine GAG excretion
Tidsramme: Baseline to Week 4, 8, 10, 26, and 52
|
Changes in levels of urine GAG excretion after multiple-dose administration of GNR-055 |
Baseline to Week 4, 8, 10, 26, and 52
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum concentration of the GNR-055
Tidsramme: Week 52
|
Assessment of the serum concentration of GNR-055 and calculation of Cmax, AUC, T1/2, Cl et other parameters after multiple-dose administration |
Week 52
|
|
GAG level in CerebroSpinal Fluid (CSF)
Tidsramme: Baseline to Week 6, 10, 26, and 52
|
Changes in levels of CSF GAG after multiple-dose administration of GNR-055 |
Baseline to Week 6, 10, 26, and 52
|
|
Serum GAG level
Tidsramme: Baseline to Week 4, 8, 10, 26, and 52
|
Changes in levels of serum GAG after multiple-dose administration of GNR-055 |
Baseline to Week 4, 8, 10, 26, and 52
|
|
Large joint range of motion
Tidsramme: Week 8, 10, 26, and 52
|
Changes over time in the large joint range of motion after multiple-dose administration of GNR-055 |
Week 8, 10, 26, and 52
|
|
Liver and spleen volumes (MRI)
Tidsramme: Baseline to Week 8, 10, 26, and 52
|
Changes over time in liver and spleen volume according to ultrasound/MRI after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
6-minute walk test
Tidsramme: Baseline to Week 8, 10, 26, and 52
|
Changes over time in the results of the 6-minute walk test after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
Left ventricular mass by EchoCG
Tidsramme: Baseline to Week 8, 10, 26, and 52
|
Changes over time in the left ventricular mass according to Echocardiography (Echo-CG) after multiple-dose administration of GNR-055 |
Baseline to Week 8, 10, 26, and 52
|
|
Lung Forced Vital Capacity (FVC)
Tidsramme: Baseline to Week 8, Week 26, and Week 52
|
Changes over time in FVC according to spirometry after multiple-dose administration of GNR-055 |
Baseline to Week 8, Week 26, and Week 52
|
|
Neurocognitive functions assessment
Tidsramme: Baseline to Week 12, 26, and 52
|
Changes over time in neurocognitive functions after multiple-dose administration of GNR-055 |
Baseline to Week 12, 26, and 52
|
|
Brain white/gray matter structures (MRI)
Tidsramme: Baseline to Week 26, and 52
|
Changes over time in the quantitative MRI brain structure parameters after multiple-dose administration of GNR-055 |
Baseline to Week 26, and 52
|
|
Serum neuromarkers
Tidsramme: Baseline to Week 24, and 52
|
Changes in levels of serum neuromarkers after multiple-dose administration of GNR-055 |
Baseline to Week 24, and 52
|
|
CSF neuromarkers
Tidsramme: Baseline to Week 24, and 52
|
Changes in levels of CSF neuromarkers after multiple-dose administration of GNR-055 |
Baseline to Week 24, and 52
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Oksana A. Markova, MD, MSc, AO GENERIUM
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Sygdomme i nervesystemet
- Bindevævssygdomme
- Genetiske sygdomme, medfødte
- Intellektuel handicap
- Neurologiske manifestationer
- Psykiske lidelser
- Kognitiv dysfunktion
- Kognitionsforstyrrelser
- Metaboliske sygdomme
- Neurokognitive lidelser
- Hunters syndrom
- Neuroadfærdsmæssige manifestationer
- Lysosomale opbevaringssygdomme
- Heredodegenerative lidelser, nervesystem
- Genetiske sygdomme, X-forbundet
- Mucopolysaccharidosis type II
- Metabolisme, medfødt
- Iduronat-2-sulfatase
- Modificeret I2S-protein
- Mental retardering, X-Linked
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Metabolisme, medfødte fejl
- Død
- Neurodegenerative sygdomme
- Neuroudviklingsforstyrrelser
- Kulhydratmetabolisme, medfødte fejl
- Mucinoser
- Død, Sudden
- Mucopolysaccharidoser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Hud- og bindevævssygdomme
- Tegn og symptomer
- Spædbarnsdød
- Neurologiske manifestationer
- Kognitiv dysfunktion
- Psykiske lidelser
- Genetiske sygdomme, medfødte
- Intellektuel handicap
- Sygdomme i nervesystemet
- Neuroadfærdsmæssige manifestationer
- Metaboliske sygdomme
- Neurokognitive lidelser
- Mucopolysaccharidosis II
- Bindevævssygdomme
- Genetiske sygdomme, X-forbundet
- Kognitionsforstyrrelser
- Lysosomale opbevaringssygdomme
- Heredodegenerative lidelser, nervesystem
- Pludselig spædbarnsdød
- X-Linked Intellektuel Handicap
Andre undersøgelses-id-numre
- IDB-MPS-II-III
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .